Laromestrocel (lomecel-B) - (ELPIS II)

June 4, 2026: Longeveron Inc. (NASDAQ: LGVN) announced it will participate in the BIO International Convention (June 22–25, 2026, San Diego) and deliver a corporate presentation covering the company and its stem cell therapy laromestrocel (Lomecel-B) on Wednesday, June 24 at 2:15pm PT (Theater 4). The company said executives will meet with potential partners to discuss strategic/licensing opportunities across laromestrocel programs in Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD), Pediatric Dilated Cardiomyopathy (PDCM), and Aging-related Frailty (AF).

Clinical catalyst: Longeveron stated it has completed enrollment in the Phase 2b ELPIS II trial in HLHS, with top-line data anticipated in August 2026. It also referenced prior positive initial results across five clinical trials: Phase 1 & 2 in AD, Phase 1 & 2 in AF, and Phase 1 in HLHS.

Regulatory status noted: FDA designations for HLHS (Orphan Drug, Fast Track, Rare Pediatric Disease) and for AD (RMAT and Fast Track). The company also discussed pursuing partnering to accelerate development and potentially support a future BLA path after ELPIS II data.